Human Factors for Autoinjectors: What RA Teams Expect in the Device File
Published 2026-10-27 · Keywords: autoinjector human factors
Human factors evidence is where device suppliers and drug sponsors most often misunderstand each other’s responsibilities. The supplier owns the device-side inputs — the design behaviours that make safe use possible; the sponsor owns the use-related validation that lands in the submission. RA teams expect both, clearly separated, and they expect the device supplier’s contribution to arrive as testable facts rather than adjectives.
The device-side inputs, itemized
| Device input | What it is | Why the file needs it |
|---|---|---|
| Activation workflow | The fixed user sequence — e.g. WH-DF’s two-step push-on-skin activation | The use script your validation studies will follow |
| Activation force | The force the user applies, measured | Ergonomics evidence, incl. limited-hand-strength users |
| Dose-setting behaviour | Dial detents, step feedback on adjustable platforms (e.g. WH-DG’s 0.01 mL steps) | Evidence each titration step is perceivable |
| End-of-dose signal | Audible/visual confirmation behaviours | Evidence the user knows delivery completed |
| Dose window legibility | Display design and unit configurability | Reading evidence across the user range |
| Cartridge-change sequence | The defined replacement workflow on reusable platforms | Reuse-related use errors addressed by design |
Each of these arrives as a specification line with a test behind it — which is the difference between a device file that feeds validation studies and one that needs reverse-engineering.
The responsibility split, stated plainly
The device supplier designs for safe use, characterizes the device’s use-relevant behaviours, and documents them. The drug sponsor plans and executes the use-related validation — simulated-use and, where required, real-use studies — in the context of their drug, its users and its labeling. A supplier who offers to “handle your HFE validation” is blurring a boundary that reviewers check; a supplier who hands over complete, tested device behaviours is doing their half properly.
Design choices change the validation burden, and that is a sourcing-relevant fact. A fixed-dose autoinjector with push-on-skin activation has a shorter use script than a dial-dose pen — no dose-setting steps to validate, no dial-reading errors to characterize. That simplicity is one of the real reasons fixed-dose platforms are preferred where the label allows them. Where titration requires a dial, the step feedback design (each increment perceivable) is what keeps the validation study manageable.
How to verify the device-side package
Ask for the use-relevant specification set: activation workflow description, measured activation force, dose-step feedback behaviour, end-of-dose signal specification, and the cartridge-change sequence for reusable platforms. Then hand the set to your human-factors lead and ask one question: “can we plan the validation study from this?” If the answer is yes, the supplier has done their half.
What this does not cover
Use-related risk analysis, simulated-use study protocols and submission formatting belong to the sponsor and their HFE consultants. Device performance testing per standards is covered separately — see what ISO 11608-5 actually tests.
Next step: request the use-relevant specification set for your candidate platform — the tested facts your HFE plan will stand on. Start the inquiry.
Related reading
Talk to NOVIXPEN about your program
Send your container format, annual volume and target market — we reply with the platform match, documentation set and written quotation within one working day.
Start the inquiry